Evidence map›Paper›PMID 40492163›Full record

ArticleRadiology case reports2025

Successful long-term survival following lipiodol chemoembolization for hepatocellular carcinoma in Alagille syndrome: A case report.

Imad Akasbi, Ismail Chaouche, Nizar El Bouardi, Amal Akammar, Hajar O Chahdi, Ismail Zerrari, Maria Lahlali, Hakima Abid, Badr Alami, Nada Lahmidani and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Imad AkasbiAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Ismail ChaoucheAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Nizar El BouardiAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Amal AkammarRadiology Department, Mother and Child Hospital, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Hajar O ChahdiRadiology Department, Mother and Child Hospital, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Ismail ZerrariGastroenterology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Maria LahlaliGastroenterology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Hakima AbidGastroenterology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Badr AlamiAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Nada LahmidaniGastroenterology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Meryem BoubbouRadiology Department, Mother and Child Hospital, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Ibrahimi Sidi AdilGastroenterology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
Mustapha MaaroufiAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.
My Youssef Alaoui LamraniAdult Radiology Department, CHU Hassan II, Sidi Mohammed Ben Abdellah University, Fez, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alagille syndrome is a rare genetic disorder causing multisystem complications, including biliary abnormalities, chronic liver disease, and rarely, hepatocellular carcinoma (HCC), which is difficult to manage due to liver dysfunction and vascular abnormalities. We report a 29-year-old female, diagnosed with Alagille syndrome in infancy, who developed infiltrative HCC at age 20 and underwent lipiodol-based transarterial chemoembolization (TACE) in 2015, with a second session in 2016 for recurrence. Remarkably, she has achieved an exceptional 9-year survival post-treatment with stable imaging and no recurrence, a highly uncommon outcome for HCC in Alagille syndrome, highlighting TACE's potential as an effective palliative treatment for HCC in Alagille syndrome, particularly for patient's ineligible for liver transplantation, and underscoring the need for further studies on locoregional therapies in this rare population.

Indexed as

Alagille syndromeHCCLipiodol chemoembolization

Identifiers

PMID40492163
PMCPMC12148378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.